effect on ankyrin 1(ANK1) and CD40 ligand(CD40L). Methods：A total of 134 patients with stable coronary heart disease were divided into two groups. The control group was treated with placebo based on conventional treatment， and the observation group was treated with Qingxin Jieyu prescription based on conventional treatment. The clinical effect and outcome of the two groups were analyzed，and the levels of ANK1， CD40L and keratin 8(KRT8) were monitored. Results： The total effective rate was 80.60% in the observation group， higher than that of 64.18% in the control group，the difference being significant(P＜0.05). Before treatment， there was no significant difference in the comparison of the levels of ANK1， CD40L and KRT8 between the two groups(P＞0.05). The levels of ANK1， CD40L and KRT8 in both groups were improved when respectively compared with those before treatment， and those in the observation group were lower than those in the control group(P＜0.05). The incidence of major composite endpoint events was 1.49% in the observation group， lower than that of 10.45% in the control group(P＜0.05). The incidence of secondary composite endpoint events was 1.49% in the observation group， lower than that of 4.48% in the control group， there being no significant difference(P＞0.05). Conclusion： Qingxin Jieyu prescription for stable coronary heart disease， can regulate the expression levels of ANK1， CD40L and KRT8 in patients， reduce the incidence of composite endpoint events， and improve the curative effect.